Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.
Cancer Res. 2010 Jan 1;70(1):99-108. doi: 10.1158/0008-5472.CAN-09-1882. Epub 2009 Dec 8.
Immune tolerance to tumors is often associated with accumulation of myeloid-derived suppressor cells (MDSC) and an increase in the number of T-regulatory cells (Treg). In tumor-bearing mice, MDSCs can themselves facilitate the generation of tumor-specific Tregs. In this study, we demonstrate that expression of the immune stimulatory receptor CD40 on MDSCs is required to induce T-cell tolerance and Treg accumulation. In an immune reconstitution model, adoptive transfer of Gr-1+CD115+ monocytic MDSCs derived from CD40-deficient mice failed to recapitulate the ability of wild-type MDSCs to induce tolerance and Treg development in vivo. Agonistic anti-CD40 antibodies phenocopied the effect of CD40 deficiency and also improved the therapeutic efficacy of IL-12 and 4-1BB immunotherapy in the treatment of advanced tumors. Our findings suggest that CD40 is essential not only for MDSC-mediated immune suppression but also for tumor-specific Treg expansion. Blockade of CD40-CD40L interaction between MDSC and Treg may provide a new strategy to ablate tumoral immune suppression and thereby heighten responses to immunotherapy.
肿瘤免疫耐受通常与髓源抑制细胞(MDSC)的积累和 T 调节细胞(Treg)数量的增加有关。在荷瘤小鼠中,MDSC 本身可以促进肿瘤特异性 Treg 的产生。在这项研究中,我们证明了 MDSC 上免疫刺激受体 CD40 的表达是诱导 T 细胞耐受和 Treg 积累所必需的。在免疫重建模型中,从 CD40 缺陷型小鼠中过继转移 Gr-1+CD115+单核 MDSC 未能重现野生型 MDSC 在体内诱导耐受和 Treg 发育的能力。激动性抗 CD40 抗体模拟了 CD40 缺陷的作用,并且还提高了 IL-12 和 4-1BB 免疫疗法治疗晚期肿瘤的疗效。我们的研究结果表明,CD40 不仅对 MDSC 介导的免疫抑制是必需的,而且对肿瘤特异性 Treg 的扩增也是必需的。阻断 MDSC 和 Treg 之间的 CD40-CD40L 相互作用可能为消除肿瘤免疫抑制并增强对免疫治疗的反应提供一种新策略。